S. Atwell

发表

Structure of the C‐terminal domain of Saccharomyces cerevisiae Nup133, a component of the nuclear pore complex

Seung Joong Kim, Josef D. Franke, A. Sali, 2011, Proteins.

Structures of the autoproteolytic domain from the Saccharomyces cerevisiae nuclear pore complex component, Nup145

Seung Joong Kim, Josef D. Franke, A. Sali, 2010, Proteins.

Atomic structure of the nuclear pore complex targeting domain of a Nup116 homologue from the yeast, Candida glabrata

Seung Joong Kim, Josef D. Franke, A. Sali, 2012, Proteins.

Structure of a putative BenF‐like porin from Pseudomonas fluorescens Pf‐5 at 2.6 Å resolution

D. Baker, A. Sali, J. M. Sauder, 2010, Proteins.

Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface

Andrew Leaver-Fay, Brian Kuhlman, Steven M Lewis, 2014, Nature Biotechnology.

Predicting the Conformational Variability of Abl Tyrosine Kinase using Molecular Dynamics Simulations and Markov State Models.

M. Vieth, B. Roux, D. Clawson, 2018, Journal of chemical theory and computation.

Structure of a copper-mediated base pair in DNA.

P. Schultz, S. Atwell, E. Meggers, 2001, Journal of the American Chemical Society.

Protein production and purification

K. Gunsalus, G. Montelione, J. Bray, 2008, Nature Methods.

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

Stephen K Burley, Spencer Emtage, Shane Atwell, 2009, Molecular Cancer Therapeutics.

Emerging trends in bispecific antibody and scaffold protein therapeutics

S. Atwell, S. Demarest, P. Verdino, 2018 .

Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing

S. Atwell, A. Pustilnik, Carolyn Ho, 2020, bioRxiv.

A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase*

Stephen K Burley, Shane Atwell, S. Burley, 2004, Journal of Biological Chemistry.

Therapeutic Antibody Engineering To Improve Viscosity and Phase Separation Guided by Crystal Structure.

Qing Chai, Shane Atwell, S. Atwell, 2016, Molecular pharmaceutics.

Structural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibody

S. Atwell, D. Witcher, J. Boyles, 2016, Protein science : a publication of the Protein Society.

Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library.

J. Wells, S. Atwell, J. Ridgway, 1997, Journal of molecular biology.

STRUCTURE NOTE Structure of the C-terminal domain of Saccharomyces cerevisiae Nup133, a component of the nuclear pore complex

Seung Joong Kim, Josef D. Franke, A. Sali, 2011 .

Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease

D. Clawson, S. Atwell, N. Hu, 2019, mAbs.

Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Can

Brandon J. Margolis, S. Atwell, Matthew R. Lee, 2017, Journal of Medicinal Chemistry.

Determination of L-AP4-bound human mGlu8 receptor amino terminal domain structure and the molecular basis for L-AP4's group III mGlu receptor functional potency and selectivity.

S. Atwell, J. Ho, J. Monn, 2018, Bioorganic & medicinal chemistry letters.

Development of a high-throughput screen for protein catalysts: application to the directed evolution of antibody aldolases.

P. Schultz, S. Atwell, A. Varvak, 2003, Angewandte Chemie.

Structures of PHR domains from Mus musculus Phr1 (Mycbp2) explain the loss-of-function mutation (Gly1092-->Glu) of the C. elegans ortholog RPM-1.

Kevin T Bain, Stephen K Burley, Shane Atwell, 2010, Journal of molecular biology.

Metabotropic Glutamate Receptor

J. F. Soriano, P. Ornstein, S. Atwell, 2016 .

Selection for improved subtiligases by phage display.

S. Atwell, J A Wells, S Atwell, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Structural plasticity in a remodeled protein-protein interface.

S. Atwell, M. Ultsch, A. D. de Vos, 1997, Science.

Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective

D. McKinzie, D. Clawson, S. Atwell, 2015, Journal of medicinal chemistry.

Synthesis and pharmacological characterization of C4-disubstituted analogs of 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: identification of a potent, selective metabotropic glutamate receptor agonist and determination of agonist-bound human mGlu2 and mGlu3 amino terminal domain struct

D. McKinzie, D. Clawson, S. Atwell, 2015, Journal of medicinal chemistry.

Structure of the regulatory domains of the Src-family tyrosine kinase Lck

Michael J. Eck, S. Harrison, S. Shoelson, 1994, Nature.

From big molecules to smaller ones

W. Delano, S. Atwell, M. Ultsch, 1999 .

Channel Gating Regulation by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) First Cytosolic Loop*

G. Lukács, S. Atwell, H. Lewis, 2015, The Journal of Biological Chemistry.

Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant.

John F Hunt, Diana Wetmore, Spencer Emtage, 2010, Protein engineering, design & selection : PEDS.

Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.

J. F. Soriano, P. Ornstein, S. Atwell, 2016, Journal of medicinal chemistry.

Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis

Zhengrong Yang, Shane Atwell, Chi Wang, 2010, Protein science : a publication of the Protein Society.

Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide‐binding domain 1

Zhengrong Yang, John F Hunt, Diana Wetmore, 2010, Protein science : a publication of the Protein Society.

Epitope topography of agonist antibodies to the checkpoint inhibitory receptor BTLA.

C. Ware, S. Atwell, Carolyn Ho, 2023, Structure.

Computationally Designed Bispecific Antibodies using Negative State Repertoires.

B. Kuhlman, A. Leaver-Fay, S. Atwell, 2016, Structure.

Structural Basis for ( S)-3,4-Dicarboxyphenylglycine (DCPG) As a Potent and Subtype Selective Agonist of the mGlu8 Receptor.

S. Atwell, M. Bures, J. Ho, 2018, Journal of medicinal chemistry.

High throughput protein production and crystallization at NYSGXRC.

Stephen K Burley, Kevin Bain, Spencer Emtage, 2008, Methods in molecular biology.

Synthesis and Pharmacological Characterization of C4β-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu3 Receptor Agon

K. Adragni, D. McKinzie, D. Clawson, 2018, Journal of Medicinal Chemistry.

Resource Computationally Designed Bispecific Antibodies using Negative State Repertoires Graphical Abstract Highlights

Andrew Leaver-Fay, Brian Kuhlman, Karen J. Froning, 2016 .